Meclinertant

DB06455InvestigationalSmall molecule

Investigated for use/treatment in colorectal cancer, prostate cancer, schizophrenia and schizoaffective disorders, psychosis, depression, and lung cancer.

Mechanism: Pharmacologically active on Neurotensin receptor type 1
Curator reviewed
Primary indication: Investigated for use/treatment in colorectal cancer, prostate cancer, schizophrenia and schizoaffective disorders, psychosis, depression, and lung cancer.Curator reviewed
Formula / weight: C₃₂H₃₁ClN₄O₅ · 587.07 g/mol (avg)
Also known as: Reminertant
Code names: SR-48692

Resolves to

Compound

UNII5JBP4SI96HCAS146362-70-1ChEMBLCHEMBL506981ChEBI125516

Structure

InChIKeyDYLJVOXRWLXDIG-UHFFFAOYSA-NSMILESCOC1=CC=CC(OC)=C1C1=CC(=NN1C1=C2C=CC(Cl)=CC2=NC=C1)C(=O)NC1(C2CC3CC(C2)CC1C3)C(O)=O

Targets

P30989NTSR1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Meclinertant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account